



# THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### Concise review

**Citation for published version:**

Heslop, JA, Hammond, TG, Santeramo, I, Tort Piella, A, Hopp, I, Zhou, J, Baty, R, Graziano, EI, Proto Marco, B, Caron, A, Sköld, P, Andrews, PW, Baxter, MA, Hay, DC, Hamdam, J, Sharpe, ME, Patel, S, Jones, DR, Reinhardt, J, Danen, EHJ, Ben-David, U, Stacey, G, Björquist, P, Piner, J, Mills, J, Rowe, C, Pellegrini, G, Sethu, S, Antoine, DJ, Cross, MJ, Murray, P, Williams, DP, Kitteringham, NR, Goldring, CEP & Park, BK 2015, 'Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies', *Stem Cells Translational Medicine*, vol. 4, no. 4, pp. 389-400.  
<https://doi.org/10.5966/sctm.2014-0110>

**Digital Object Identifier (DOI):**

[10.5966/sctm.2014-0110](https://doi.org/10.5966/sctm.2014-0110)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

Stem Cells Translational Medicine

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



# Workshop review: Understanding and assessing the risks of stem cell-based therapies

**James A. Heslop<sup>2\*</sup>, Thomas G. Hammond<sup>3\*</sup>, Ilaria Santeramo<sup>4\*</sup>, Agnès Tort Piella<sup>2\*</sup>, Isabel Hopp<sup>4</sup>, Jing Zhou<sup>4</sup>, Roua Baty<sup>5</sup>, Enrique I. Graziano<sup>6</sup>, Bernabé Proto Marco<sup>6</sup>, Alexis Caron<sup>7</sup>, Patrik Sköld<sup>8</sup>, Peter W. Andrews<sup>9</sup>, Melissa A. Baxter<sup>10</sup>, David C. Hay<sup>11</sup>, Junnat Hamdam<sup>12</sup>, Michaela E. Sharpe<sup>13†</sup>, Sara Patel<sup>14</sup>, David R. Jones<sup>15</sup>, Jens Reinhardt<sup>16</sup>, Erik H.J. Danen<sup>17</sup>, Uri Ben-David<sup>18</sup>, Glyn Stacey<sup>19</sup>, Petter Björquist<sup>20</sup>, Jacqueline Piner<sup>21</sup>, John Mills<sup>22</sup>, Cliff Rowe<sup>23</sup>, Giovanni Pellegrini<sup>24</sup>, Swaminathan Sethu<sup>25</sup>, Daniel J. Antoine<sup>2</sup>, Michael J. Cross<sup>2</sup>, Patricia Murray<sup>4</sup>, Dominic P. Williams<sup>26</sup>, Neil R. Kitteringham<sup>2</sup>, Chris E.P. Goldring<sup>1,2</sup> and B. Kevin Park<sup>2</sup>**

1 IMI SafeSciMET, Avenue de la Toison d'Or 56-60 B-1060, Brussels, Belgium

2 MRC Centre for Drug Safety Science, Division of Molecular & Clinical Pharmacology, the Institute of Translational Medicine, the University of Liverpool, Liverpool L69 3GE, UK

3 Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, Klingelbergstrasse 50, Pharmazentrum, University of Basel, Switzerland

4 The Institute of Translational Medicine, the University of Liverpool, Liverpool L69 3GE, UK

5 The Institute of Integrative Biology, the University of Liverpool, Liverpool L69 7ZB, UK

6 Laboratorios Almirall, S. A. Laureia Miro, 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain

7 SANOFI - Research & Development, Disposition, Safety and Animal Research, 3, digue d'Alfortville, 94140 Alfortville, France

8 Uppsala biomedicinska centrum BMC, Husarg. 3 Uppsala University, Sweden

9 Centre for Stem Cell Biology, Department of Biomedical Science, the University of Sheffield, Western Bank, Sheffield, S10 2TN UK

10 Developmental & Regenerative Biomedicine, School of Biomedicine, Faculty of Human and Medical Sciences, 3rd Floor AV Hill, the University of Manchester, Oxford Road, Manchester, M13 9PT, UK

11 MRC Centre for Regenerative Medicine, University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, U.K

12 Department of Gastroenterology, Hepatology and Infectious diseases, Heinrich-Heine University Düsseldorf, Universitätsstrasse 1, 40225, Düsseldorf, Germany

13 OakMore Solutions Ltd, Uplees Road, Faversham, Kent, ME13 0QR, U.K

14 ReNeuron Limited, 10 Nugent Road, Surrey Research Park, Guildford, Surrey GU2 7AF, UK

15 Medicines and Healthcare Products Regulatory Agency (MHRA), 151 Buckingham Palace Road, Victoria, London SW1W 9SZ, UK

16 Paul Ehrlich Institut, Paul-Ehrlich-Strasse 51-59, 63225 Langen, Germany

17 Faculty of Science, Leiden Academic Centre for Drug Research, Toxicology, Leiden, Netherlands

18 Stem Cell Unit, Department of Genetics, Institute of Life Sciences, The Hebrew University of Jerusalem, Givat-Ram, Jerusalem 91904, Israel

19 UK Stem Cell Bank, National Institute for Biological Standards and Control, MHRA, Hertfordshire, EN6 3QG, UK

20 Collectis AB, Arvid Wallgrens Backe 20, SE-413 46, Göteborg, Sweden

21 GSK, David Jack Centre for R&D, Park Road, Ware, Hertfordshire, SG12 0DP, United Kingdom

22 Personalised Healthcare and Biomarkers, AstraZeneca, Alderley Park, Cheshire, UK

23 CN-bio Innovations Limited, Centre for Innovation & Enterprise, Oxford University Begbroke Science Park, Begbroke, Oxfordshire, OX5 1PF, UK

24 Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 268, Zurich, CH-8057

25 School of Bio Sciences & Technology and Centre for Biomaterials Science & Technology, VIT University, Vellore, India. 632014

26 Translational Safety, Drug Safety and Metabolism, AstraZeneca, Darwin Building, Cambridge Science Park, Milton Rd, Cambridge, CB4 0FZ

\*These authors contributed equally

†Present address: Cell Therapy Catapult, Biomedical Research Centre, R&D 16th Floor Tower Wing, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK

## Abstract

The field of stem cell therapeutics is moving ever closer to widespread application in the clinic. However, despite the undoubted potential held by these therapies, the balance between risk and benefit remains difficult to predict. As in any new field, a lack of previous application in man and gaps in the underlying science mean that regulators and investigators continue to look for a balance between minimizing potential risk and ensuring therapies are not needlessly kept from patients. Here, we attempt to identify the important safety issues, assessing the current advances in scientific knowledge and how these may translate to clinical therapeutic strategies in the identification and management of these risks. We also investigate the tools and techniques currently available to researchers during pre-clinical and clinical development of stem cell products, their utility and limitations and how these tools may be strategically used in the development of these therapies. We conclude that ensuring safety through cutting-edge science and robust assays, coupled with regular and open discussions between regulators and academic/industrial investigators are likely to prove the most fruitful route to ensuring the safest possible development of new products.

**Abbreviations:** (human/murine) induced pluripotent stem cell, (h/m)iPSC; (human/murine) embryonic stem cell, (h/m)ESC; mesenchymal stem cell, MSC; hematopoietic stem cells, HSCs; adult stem cell, ASC; graft versus host disease, GVHD; major histocompatibility complex, MHC; minor histocompatibility complex, mHC; Oct4, Sox2, Klf4, c-Myc, OSKM; human leukocyte antigen, HLA; Magnetic Resonance imaging, MRI; computed tomography, CT; positron emission tomography, PET; single photon emission computed tomography, SPECT; superparamagnetic iron oxide particles, SPIO; 9-[4-[<sup>18</sup>F]Fluoro-3-(hydroxymethyl)butyl]guanine, [<sup>18</sup>F]FHBG; perfluorocarbon, PFC; fluorine-19, <sup>19</sup>F; single nucleotide polymorphism, SNP; Food and drug administration, FDA; Medicines and healthcare products regulatory agency, MHRA. QD, quantum dots; G/RFP, green or red fluorescent protein

## I. Introduction

Stem cell therapies are moving rapidly into clinical application. While it is important that these therapies are advanced into the clinic, their safety must be continually evaluated. Here we outline the known risks of stem-cell therapeutics (Figure S1) and discuss how they can be assessed and managed through preclinical and clinical trials. This review is the output of an IMI SafeSciMET workshop held at the University of Liverpool.

A key issue in the understanding of the safety concerns is the breadth of the human stem cell field, with several cell types falling under the umbrella term of 'stem cell':

- **Human embryonic stem cells ((h)ESCs)** are pluripotent cells, first isolated from human embryos in 1998 by James Thompson<sup>1</sup>.
- **Induced pluripotent stem cells ((h)iPSCs)** were first reported in 2006. Somatic cells were reprogrammed using the transcription factors Oct4, Sox2, Klf4 and c-Myc (OSKM), to a pluripotent stem cell state<sup>2,3</sup>.
- **Adult stem cell (ASCs)** covers several cell types including mesenchymal and hematopoietic stem cells and tissue-specific progenitors which reside in the human body throughout an individual's life and in comparison to pluripotent stem cells, generally have a more limited expansion and differentiation capacity<sup>4,5</sup>.

Some adult stem cell-based therapies are clinically available, such as bone marrow or cord blood transplants containing hematopoietic stem cells<sup>6,7</sup>, skin grafts for burns<sup>8</sup>, and mesenchymal stem cells for graft vs host disease (GVHD) in children (Canada and New Zealand)<sup>9</sup>.

Additionally, over 3000 trials associated with stem cells are currently collated in the international clinical trial registry platform ([www.who.int/trialsearch](http://www.who.int/trialsearch)). The majority of these are adult stem cell-based therapies, likely attributable to the longer established use of these cells.

The registry also includes the first pluripotent-based therapies to be subjected to clinical trials; table 1 highlights the narrow scope of these hESC/hiPSC-derived therapeutics, with 9 of the 10 treatments associated with macular dystrophy or degeneration, including the recently approved first human trial using hiPSCs<sup>10</sup>. Use of the eye as a first application of these cells is ideal: the graft size required is small, retinal pigment epithelial cells are easily differentiated to high purity, and the grafts can be visualized non-invasively, all contributing to a lower risk profile than hESC/hiPSC grafts in less accessible organs<sup>11,12</sup>. Other iPSC-related trials listed on the registry are related to the generation of genotype or disease-specific iPSC lines for use as disease/genotype models and stem cell banks, highlighting the broad appeal of hiPSCs.

Despite the basic technology being in place to produce a wider range of therapies, many aspects of the field, including safety, remain incompletely understood, contributing to the cautious translation from theoretical benefits to clinical application.

## II. Stem cell risk factors

### II.I Tumorigenic potential

A major concern over the use of stem cell therapies is the perceived risk of tumorigenicity. This is exemplified by the investigation of a tumor which developed four years after fetal neural stem cell transplantation for ataxia telangiectasia<sup>13</sup>. Subsequent analysis found that the tumor was derived from the transplanted material. Similar cases have also been reported in the treatment of spinal injury with olfactory mucosal cell transplantation; following presentation with back pain 8 years after the treatment, the patient was found to have developed a mucosal-like mass at the transplant location<sup>14</sup>. This study is particularly pertinent given that the treatment used adult stem cells, which are often considered to be less tumorigenic than fetal or pluripotent stem cells, and the recent ground-breaking treatment of spinal injury with olfactory ensheathing cells<sup>15</sup>. In this study, the authors report no adverse effects after 19 months; however, tumors from stem cell grafts can arise many years after transplantation, highlighting the need for extensive follow-up programmes to reduce patient risk.

The capacity for undifferentiated pluripotent stem cells to form teratomas *in vivo* is of particular concern<sup>16</sup>. Therefore, these cells will be differentiated before transplantation. However, the risk remains that not all cells will be fully differentiated. One study showed that despite functional liver engraftment, hESC-derived hepatocyte-like cells transplanted into immunocompromised mice developed splenic and liver tumors containing endodermal and mesodermal cell types<sup>17</sup>. Teratomas have also been shown to be able to form from as little as 0.2% SSEA-1-positive pluripotent cells, demonstrating that, even at high levels of purity, teratoma formation potential remains<sup>18</sup>.

It is therefore vital to prevent undifferentiated cells passing through to the differentiated cell population. Techniques to address this problem include small molecules targeting stearyl-CoA desaturase-1, which selectively causes cell death in undifferentiated iPSC/ESCs<sup>19</sup>. However, current analytical techniques are not reliably sensitive enough to detect the removal of all pluripotent cells<sup>20</sup>. Therefore, it is important to take other factors, such as the disease and the number of cells transplanted into account, as these will likely alter the chances of subsequent teratoma formation<sup>21</sup>. Recent work has alleviated some concerns, a non-human primate model for autologous transplants showed that iPSC-derived mesodermal stromal-like cells went on to form functional tissue, without teratoma formation<sup>22</sup>.

Human studies are the only true way to ascertain the teratoma risk in man. The first human studies were conducted by Geron in 2009, using hESC-derived oligodendrocyte progenitor cells for spinal injury treatment<sup>23</sup>. The trials were halted for financial reasons, but in the few patients treated, no tumors have been reported<sup>24</sup>. Clinical trials investigating the use of hESC- and iPSC-derived retinal pigmented epithelial cells in macular degeneration are currently ongoing<sup>11</sup> and just starting<sup>10</sup>, respectively, with no tumor formation reported as yet. If successful, these trials are likely to alleviate some of the concerns surrounding tumorigenesis from pluripotent stem cells.

Pluripotent cells can be cultured indefinitely *in vitro*, making scale-up relatively straightforward. However, during expansion the cells are susceptible to chromosomal aberrations and karyotype abnormalities<sup>25-32</sup>, potentially due to the artificial conditions in which the cells are cultured, increasing the potential for post-transplant malignancy. Pioneering work has investigated these aberrations, commonly found at chromosomes 1, 12, 17 and 20, at higher resolution; however, it remains to be

seen if the 'culprit' genes can be identified for screening<sup>26-28, 30-36</sup>. It is clear that smaller genomic changes also occur, often at a level not readily detected by standard G-banding<sup>26</sup>; the significance of these changes to safety is unclear. Much work has been focused on the removal of pluripotent stem cells from the transplanted material; however techniques which allow for the removal for genotypically compromised cells would be of equal benefit to the therapeutic safety profile<sup>37</sup>. Karyotypical changes are not limited to pluripotent cells, with ASCs also thought to develop abnormalities during *in vitro* culture<sup>34</sup>; however, these findings have been debated, as demonstrated by the correspondence between Sensebe *et al.*,<sup>38</sup> and Ben-David *et al.*,<sup>39</sup>.

iPSCs have additional safety concerns. The development of non-integrative reprogramming techniques, utilizing direct transfection of proteins or mRNAs, Sendai viruses or episomal plasmids, has reduced concerns regarding incomplete promoter silencing and genomic disruptions of traditional techniques<sup>40-43</sup>. Some have also replaced the potentially oncogenic OSKM reprogramming factors with Sall4, Nanog, Esrrb, and Lin28<sup>44</sup>; these factors are thought to be less efficient, but derive higher quality iPSCs with reduced aberrations in histone variant 2A.X, which has been shown to be a key determinant of iPSC/ESC quality and developmental potential<sup>45</sup>. Others have utilized microRNAs and small molecules to reprogram somatic cells<sup>46, 47</sup>; however, at the time of writing, these reports are yet to be repeated.

Additional studies investigating the genomic integrity of iPSCs have shown that DNA damage sustained during reprogramming may not be fully repaired in the resulting cells<sup>48</sup>. Furthermore, reprogramming cord blood cells reduced the number of DNA mutations when compared to dermal fibroblasts<sup>49</sup>, suggesting that reprogramming from neonatal or more stem-like cells may be theoretically safer, albeit more challenging to obtain.

## *II.II Immunogenic potential*

Maintaining functional immunologic tolerance of stem cells and their derivatives is crucial. Rejection is considered to be due to a mismatch in expression of human leukocyte antigens (HLA), minor histocompatibility complex (mHC) antigens and ABO blood group antigens following allogeneic transplant (Figure S2). Generally, allogeneic matching for both HLA and mHC is not feasible due to extensive polymorphisms.

Undifferentiated ASC immunogenicity studies are particularly important, as, unlike pluripotent cells, they can be administered without differentiation. Mesenchymal stem cells (MSCs) have a unique capacity amongst ASCs to modulate the immune response through a HLA-independent<sup>50</sup> dampening of inflammatory cytokine release<sup>51-53</sup>. Additional low HLA-I and no extracellular HLA-II<sup>51</sup> alongside little or no expression of B- and T-cell co-stimulatory molecules<sup>54, 55</sup> on MSCs, suggest a potential to both modulate and avoid immune surveillance.

Other ASCs, such as hematopoietic stem cells (HSCs) have also demonstrated some immune avoidance capabilities<sup>56, 57</sup>, but allogeneic transplants are still susceptible to rejection<sup>58</sup>. Moreover, the vast experience with the use of allogeneic HSC transplants for the treatment of haematological malignancies and other conditions has shown the potential for GVHD as a result of allogeneic T-cell infiltration from the graft. This represents a major risk factor and cause of patient morbidity and mortality, with ~15% of allogeneic HSC transplants resulting in fatalities<sup>59</sup>. This is a large and important topic which is well-reviewed by Blazar *et al.*,<sup>60</sup>. Interestingly, MSCs have been used for the treatment

of GVHD (Prochymal®)<sup>9, 61, 62</sup>. This has led some to suggest that MSCs could be used as part of the stem cell transplant to reduce the potential for both GVHD and graft rejection<sup>63</sup>.

Due to tumorigenic risk, clinical administration of pluripotent stem cells is likely to be in the form of a differentiated population, thus any immunogenic assessment should focus on the differentiated product<sup>64</sup>. It is generally accepted that there is little to no rejection in autologous cells, even following *in vitro* culture. Therefore, research has focused on developing stem cells which are genetically identical to the recipient. Recently, somatic cell nuclear transfer was achieved in humans, allowing for the isolation of hESCs expressing the donor genotype<sup>65, 66</sup>.

iPSC-based therapy remains the most promising technique to realizing pluripotent autologous therapy. Whilst initial reports suggested immunogenicity in syngeneic transplants<sup>67</sup>, two subsequent studies found no evidence of acute or chronic immunogenicity towards differentiated iPSCs (both spontaneous and directed)<sup>68, 69</sup>. Further, de Almeida *et al.*, reported that, in contrast to rejected iPSCs, syngeneic iPSC-derived endothelial cells were accepted in mice, demonstrating a comparable tolerogenic response to syngeneic primary endothelial cells<sup>70</sup>. Direct comparison of autologous and allogeneic transplanted iPSC-derived neurons in non-human primates also revealed minimal immune response in autologous transplants; whereas allogeneic transplants were immunogenic<sup>71</sup>. Therefore, current evidence points towards immunological tolerance of autologous terminally differentiated transplanted stem cells.

The timescale and costs associated with personalized therapies may mean that they are used as an alternative option when HLA matching cannot be achieved from stem cell banks containing carefully selected donor cell-lines<sup>72-74</sup>. A second consideration is for disorders in which their etiology is genetically-linked, and whether patient-derived transplanted material containing the diseased genotype would have therapeutic efficacy; autologous cells in such cases may require gene therapy.

One method of dealing with the immune response to cell grafts is encapsulation<sup>75, 76</sup>. Encapsulation reduces interaction with immune cells and consequently reduces the risk of rejection, whilst maintaining efficacy through the movement of factors (e.g. cytokines) across a semi-permeable membrane. Furthermore, encapsulation may also prevent tumors from reaching tissues outside the capsule. Such techniques are currently being developed for use in diseases such as diabetes and may represent an elegant solution to a complex problem<sup>77-80</sup>. Notwithstanding the clear potential, the development of such a system is not trivial, and despite sustained efforts and sequential developments, the translation to a clinically effective technology has yet to be achieved<sup>81</sup>.

Another immunological consideration is the culture conditions. Cell culture and manufacturing conditions may introduce immunogenic alterations. For example, fetal bovine serum and sialic acid derivative Neu5G from mouse feeder layers, have both been shown to alter the immunogenicity of stem cells<sup>82 83</sup>. Therefore, certified animal component-free products should be used wherever possible.

## II.III Biodistribution

Biodistribution encompasses the risks associated with the migration, distribution, engraftment and long-term survival of the transplanted material.

Different routes of administration result in differential dissemination patterns and risks. Systemic administration can lead to cells becoming entrapped in the lung or microvasculature, causing dangerous side-effects, such as the pulmonary emboli reported following intravenous administration of adipose-tissue derived stem cells<sup>84</sup>. Administration in a feeding artery of the target tissue has been proposed to reduce these risks<sup>85</sup>; however, the risk of microvascular occlusions remain. Direct transplant to the targeted organ/area may reduce these risks<sup>86, 87</sup>; however, this is likely to be location-dependent and may require invasive surgery, e.g. the liver. Therefore, the chosen method must consider the target pathology, therapeutic objectives and the patient risk-benefit profile<sup>88, 89</sup>.

Once administered, up to 90% of transplanted cells are lost due to physical stress, inflammation, hypoxia, anoikis or immunogenic rejection<sup>20, 90</sup>. To achieve therapeutic efficacy, large numbers of cells may therefore be required, increasing the risk of teratoma formation<sup>21</sup> or ectopic engraftment. Thus, the minimum number of cells required for effective treatment should be ascertained as part of product development.

A recent study of neural stem cells in a model of spinal cord injury reported ectopic cell growth 9-10 weeks post-transplant at various points along the spinal cord and brainstem<sup>91</sup>. These were hypothesised to have travelled via the cerebral spinal fluid, colonized and further proliferated, highlighting the need to understand the biodistributary properties of the treatment before clinical application.

The half-life of the transplanted material is another factor which can alter the level of risk. If short, the risk associated with the transplanted material is reduced accordingly. However, if therapeutic efficacy is limited to the short-to-medium term, chronic diseases may require repeated administration and thus an understanding of the likely dosing regime is another key consideration for risk assessment.

### **III. Regulation of stem cell therapeutics**

One of the major limitations of stem cell therapeutics is the heterogeneous character and limited experience of their development. Consequently, no specific European (European Medicines Agency, EMA) or UK (Medicines and Healthcare Products Regulatory Agency, MHRA) regulatory guidance<sup>92</sup> addresses technical aspects of the drug development program in detail, e.g. type, size and duration of non-clinical studies.

Regulators have attempted to address these problems by drafting guidelines and reflection papers. The “Guideline on human cell-based medicinal products (EMA/CHMP/410869/2006)” was adopted in 2008, before the unifying regulation on advanced therapy and medicinal products came into force<sup>93</sup>, and gives a generic overview on the requirements for the licensing of cell-based medicinal products; however, the information provided is not very detailed. A subsequent reflection paper on stem cell-based medicinal products (CAT/571134/09) was adopted in 2011, focusing more specifically on stem-cell based medicinal products and also discusses the experiences gained with cell-based products, including a summary of the challenges associated with biodistribution and immunogenicity studies.



However, since no detailed requirements are defined, the applicant is still required to implement an appropriate development program that addresses the product-specific risks.

It is highly advisable to engage in discussions with the regulatory bodies early in the development of the product. Most regulatory agencies develop structures to facilitate the interaction with developers (e.g. the MHRA innovation office and the EMA innovation task force) and may provide scientific advice to assist product development.

For the development of advanced therapy medicinal products, a risk-based approach can be used as a matrix to decide which non-clinical data are needed. The (optional) risk-based approach encompasses intrinsic (cell-related) and extrinsic (manufacture-related) risks associated with the medicinal product and the subsequent development and implementation of the appropriate assays to assess these risks.

Further help with risk assessment is available in the “Guideline on the risk-based approach according to annex I, part IV of Directive 2001/83/EC applied to advanced therapy medicinal products” (EMA/CAT/CPWP/686637/2011). This document provides examples illustrating the risk-based approach. Likewise, (non-binding) guidance documents are also provided by the Food and Drug Administration (FDA) in the USA<sup>94</sup>.

As a regulatory pre-requisite, good manufacturing practice must also be followed, as well as the use of clinical grade stem cell products and procedures, free of microbiological and non-microbiological contaminants. Similar practices should be applied to pre-clinical research in order to allow predictable translation of therapies to the clinic.

The importance of regulation is highlighted by the report on the unregulated use of fetal brain-derived olfactory ensheathing cells for the treatment for spinal cord injuries. The authors found little-to-no benefit from the treatment, but complications including meningitis and death<sup>95</sup>. Whilst this is an extreme example, many unregulated stem cell treatments are now available across the world (well reviewed by Zarzeczny *et al.*,<sup>96</sup>). In 2011, Celltex® began offering ASC-based therapies in Texas, USA without FDA approval, igniting debate about the regulation of stem cell therapeutics<sup>97</sup>. Subsequently, the FDA won a recent court battle to regulate proliferated stem cells as biological drugs and documents encapsulating these new regulatory powers are in preparation<sup>98, 99</sup>.

## **IV. Pre-clinical and clinical assessment**

### *IV.1 Tumorigenic and immunogenic pre-clinical and clinical trials/assays*

In terms of both tumor- and immunogenicity, risk cannot be reliably assessed when the model is not predictive, so it is important to match the targeted disease phenotype to the animal or *in vitro* assay. Traditional medicinal product development routes may be appropriate (i.e. going from simple to complex, *in vitro* to *in vivo* and animal to human). However, some therapies may require multi-model studies to provide the fullest understanding of both efficacy and safety, whilst other therapies may not require an animal model as there may be little relevance. Future pre-clinical assessments may also use iPSC-derived cells as a source of a diseased phenotype as the most clinically relevant assay of therapeutic safety and efficacy.

#### *Assays for the assessment of tumorigenic potential*

The tumorigenic potential of cell-based therapies needs to be assessed throughout product development.

*In vitro* techniques, such as karyotyping, can be used to assess genomic integrity. More in-depth investigation may be required to detect smaller changes; however, without known associated changes, attributing risk is difficult. Q-PCR and flow cytometry can be used to determine the purity of the differentiated population and soft agar colony formation assays may also be used to assess the tumorigenic potential of the cell population<sup>100</sup>. However, all these indirect methods do not guarantee absence of tumors in the clinical setting.

Immune-deficient rodent models may be used to assess the direct tumorigenic potential of the transplanted material, with tumorigenic growth reported from as little as two undifferentiated ESCs<sup>101</sup>. Initial investigations may take place in an easily accessible and observable location with cell number determined by the planned assessment method. Once initial investigations are complete, tumorigenicity in the clinically relevant microenvironment should then be assessed with cell numbers equivalent to and higher than the predicted clinical dose. Deep tissue assessment by q-PCR or histopathological analysis is usually required to confirm ectopic tumor formation<sup>102, 103</sup>, but future investigations may utilize improvements in real-time cell tracking for greater information with regard to tumor location/development. Currently available imaging techniques suitable for clinical tumorigenic analysis include MRI for tumors >0.3cm and FDG-PET for tumors >1cm, with bioluminescent and photoacoustic imaging currently limited to pre-clinical studies<sup>104, 105</sup>. The use of biomarkers in clinical trials may also provide useful information, with raised blood alpha-fetoprotein (AFP) levels found in many teratomas<sup>106</sup>. Commonly used techniques for assessing tumorigenic potential *in vitro* and after clinical transplantation are presented in table 2.

Immune-deficient models lack the immune response to tumor formation. Previous reports have demonstrated a reduced capacity for tumor formation in immune-competent models when compared to immune-deficient models<sup>70, 101</sup>. Consequently, a tumor which forms in an immune-deficient model may not always form in an immune-competent model or in clinical studies.

Pre-clinical non-xenogeneic studies using animal transplant models, as shown by Hong *et al.*,<sup>22</sup> (e.g. transplanting equivalent mouse iPSC-derived cells into genetically identical/non-identical mice) used in combination with *in vitro* assays before the development of human equivalents, may therefore be the most relevant method of assessing tumorigenicity.

#### *Assays for the assessment of immunogenic potential*

Developing relevant immunogenicity assays remains challenging. Immune-competent and immune-deficient *in vivo* models lack immunogenic clinical relevance for human cells in most situations; however, in some cases they can provide useful information:

- Immune-competent models may be used to investigate the use of stem cells in immune-privileged locations, such as the eye<sup>12</sup> or as a model of allogeneic transplants.
- Immune-deficient animals varying in the extent of immune-depletion(i.e. loss of specific immune cell types) may be useful in investigating specific mechanisms of rejection<sup>107</sup>.
- Humanized models, such as the trimera mouse, have human immune cells, improving relevance<sup>108</sup>, especially for examining allogeneic grafts.

Recognizing that xenotransplantation cannot capture the human allo-immune response<sup>109</sup>, *in vitro* assays such as mixed lymphocyte reactions, may be more informative of graft immunogenicity. Moreover, using the equivalent therapy in a species suitable for modelling immunogenicity, such as the non-human primate iPSC-derived transplant models reported by Morizane *et al*<sup>71</sup>, may provide the most informative results, if technically and financially viable.

#### *IV.II Biodistribution in pre-clinical and clinical trial/assays*

Biodistribution assays inform both safety and efficacy evaluations. Whilst histopathology and PCR remain the gold standard for assessing deep tissues, here we focus on cell labelling due to its ability to monitor cell distribution/migration in real-time<sup>110</sup>. Such techniques are important for ascertaining the migratory/distribution patterns and are also informative in a tumorigenic (ectopic tumor formation) and immune (loss of cells through immune rejection) context.

Cellular imaging strategies are composed of the imaging technique and the labelling agent (figure S3). The imaging technique is usually chosen in conjunction with the labelling agent, which can be classified in two main categories: direct and indirect labelling<sup>111</sup>, summarized in table 3.

##### *Direct Labelling*

Direct labelling requires the introduction of the labelling agents into the cells before transplantation. The relative intensity of the detected signal from the introduced molecules is then used as a surrogate for cell number.

Radionuclides used for cell imaging have different half-lives, which therefore determines the length of time cells can be monitored non-invasively<sup>110</sup>; these are mainly detected using single photon emission computed tomography (SPECT) and/or positron emission tomography (PET; table 3). Studies have shown as little as  $6.2 \times 10^3$ - $2.5 \times 10^4$  cells can be detected using these methods<sup>112</sup>. However, short radionuclide half-lives mean that cell-tracking is limited to hours rather than weeks. Indium-111 oxine has a relatively long half-life (~2.8 days)<sup>112</sup> and has been shown to successfully track MSCs in preclinical models for up to 7 days<sup>113</sup>; however, signal leakage and alteration of cell phenotype limits translatability<sup>114</sup>. Clinically, hematopoietic stem cells labelled with  $^{18}\text{F}$ -FDG for acute and chronic myocardial infarction treatment were successfully tracked by PET after 20 hours<sup>115</sup>.

The use of iron oxide-labelling for MRI makes it possible to trace the cells over longer periods of time<sup>116</sup>. The most common labelling agent in pre-clinical/clinical trials is superparamagnetic iron oxide particles (SPIO), which offers the highest sensitivity and has been used to track neural stem cells in a patient for up to 3 weeks<sup>117</sup>. Generally, MRI has lower sensitivity than SPECT/PET. The number of cells used for SPIO tracking in man ranges from  $3.71 \times 10^5$  to  $17.4 \times 10^6$  cells<sup>118</sup> whilst de Vries *et al.*, were able to detect  $1.5 \times 10^5$  dendritic cells in melanoma patients<sup>119</sup>.

Alternatively, Perfluorocarbons (PFC) and Fluorine-19 ( $^{19}\text{F}$ ) MRI can be used to track cells<sup>120</sup>. Cells are labelled with PFC emulsions before transplantation and subsequently detected as hotspots by  $^{19}\text{F}$  MRI. The main advantage of this system is the low signal-to-noise ratio, due to the low endogenous  $^{19}\text{F}$  concentration, allowing for the quantification of cells at an estimated minimum sensitivity of  $10^4$ - $10^5$  cells per voxel<sup>120</sup>. This system has been successfully exploited to monitor stem cells therapies<sup>121-123</sup> and is promising for clinical applications with some PFCs approved by the FDA<sup>124</sup>. This system has been applied clinically in dendritic cells, with a reported minimum sensitivity of  $1 \times 10^5$  cells/voxel<sup>125</sup>.

### *Indirect Labelling*

Indirect labeling is the introduction of a gene encoding for a reporter recognized by a reporter probe or imaging system<sup>20</sup>. This system is highly controllable because only viable cells are able to transcribe the reporter gene<sup>126</sup>.

In MRI-based gene reporter systems, the transduced gene is typically an intracellular metalloprotein (e.g. transferrin, ferritin, tyrosinase), that traps large quantities of iron in the cytoplasm for non-invasive detection<sup>110, 126</sup>. However, the trapped iron produces long-term background which masks the viability of the cell<sup>112</sup>. Some have therefore suggested that the only transduced gene currently suitable for MRI cell tracking is Lysine-rich protein<sup>127</sup>.

In the SPECT and PET reporter gene imaging systems, a gene reporter (enzyme or receptor) requires an exogenously administered probe (tracer) to localize and quantify the stem cell product.

A number of groups successfully monitored ESCs<sup>128</sup> and MSCs<sup>129, 130</sup> in animal models, using gene reporter systems. These studies reported a reliable correlation in terms of localization, magnitude and duration of the cells *in vivo* when compared to conventional methods (immunohistochemistry and PCR). The short half-life of the probes allows a defined continuous imaging period of no more than a few hours<sup>128</sup>. However, being non-invasive, monitoring of the stem cells at regular intervals was possible for up to 4 weeks<sup>128-130</sup>. Quantitative information can be extrapolated from the percentage of injected radioisotope/gram of tissue, allowing for the quantification of the area(s) covered by the cells, but not the exact cell number<sup>129</sup>.

The use of indirect labelling is rare in a clinical setting as genetic manipulation is required<sup>131</sup>. However, the FDA has approved the PET reporter probe 9-[4-[<sup>18</sup>F] Fluoro-3-(hydroxymethyl) butyl]guanine ([<sup>18</sup>F]FHBG; IND #61,880)<sup>132</sup> for the treatment of glioblastoma multiforme. Successful tracking of T-cells was reported with no significant adverse effects<sup>133</sup>. Guidelines on how to administer and safely monitor <sup>18</sup>F-FHBG in humans have been made available<sup>134</sup>.

Optical imaging techniques are limited by exponential signal loss as depth increases, caused by scattering phenomena that occur when photons pass through the tissue<sup>110, 126</sup>. Photoacoustic tomography overcomes this problem. A short laser pulse irradiates the target tissue, causing a partial absorption of the pulse energy and conversion into heat. This increases local pressure through thermo-elastic waves and is subsequently detected by ultrasonic transducers placed outside the tissue. The image is generated by collecting all thermo-elastic waves from the arrival time<sup>135, 136</sup>. Such technology has been used to track human MSCs labeled with gold nanocages in a rodent model for 7 days<sup>104</sup>.

### *IV.III Other risks associated with the translation to the clinic*

Despite highly-controlled conditions in both cell preparations and clinical settings, infections remain a risk for patients who have received allogeneic stem cell transplants which require immune-suppression therapy<sup>137</sup>. Moreover, long-term immunosuppression has well-documented side-effects including end-organ toxicity and increased risk of cancers<sup>138</sup>.

Viral status must also be assessed in donors of allogeneic grafts. Donors of HSCs are routinely screened for hepatitis viruses, human immunodeficiency virus, cytomegalovirus and (bacterial) syphilis<sup>139, 140</sup>.

Further screening for herpes simplex virus, Epstein-Barr virus and adenoviruses may also be required in addition to screening for cell type- and location-specific viruses<sup>140</sup>. Genotype screening for donor cells has also been suggested<sup>141</sup>, with some reports of specific genetic polymorphisms associated with differential GVHD severity and outcome in allogeneic HSC transplants<sup>142, 143</sup>.

Scaffolds, aiding engraftment or delivery of cells, should also be considered for immunological potential. Such devices have been used to improve the survival of MSCs in brain injury models<sup>144, 145</sup> and some groups are attempting to use decellularized organs<sup>146</sup> as 3D scaffolds for stem cell-derived repopulation<sup>147-149</sup>. Biological scaffolds offer greater similarity to the host extracellular matrix than those of synthetic origin, improving engraftment; however, they are usually xenogeneic/allogeneic<sup>150</sup> and thus have immunogenic potential. Various techniques have been used to remove antigenic epitopes, DNA and damage-associated molecular pattern signals<sup>151-154</sup>; however, immunogenic potential remains. A comparative study of 5 commercially-available biological scaffolds demonstrated significantly elevated immune responses, including chronic inflammation and fibrosis, versus an autologous control<sup>155</sup>.

Scaffolds derived from synthetic origin are generally considered to be less immunogenic. Several synthetic biodegradable polymers have been approved by the FDA for medical applications<sup>156-158</sup>, and consequently may be used without further safety assessment. However, novel materials/uses are required to undergo safety testing in compliance with the ISO 10993 International Standard (ISO 10993: Biological evaluation of medical devices).

## **V. Conclusions**

Stem cell therapies have immense potential to alleviate, or even cure, a range of acute, chronic and debilitating diseases. However, we must ensure that these therapies are safe as well as effective, and a lot of work still remains to be done to understand and reduce any risk associated with their use.

Huge improvements in our *in vitro* techniques are needed, such as ensuring gene aberration-free expansion and improved differentiation purity, alongside the better identification of risk factors which can be routinely screened before transplantation. Furthermore, the development of models which can better predict immunological responses and cell tracking techniques with increased duration and depth capabilities would represent great improvements to the current status quo.

However, the top priority is that this work must remain focused on the clinical outcome. The most important consideration is the risk-benefit assessment for the patient. Whilst a stem cell therapy, like many drugs, may not be perfectly safe, the benefit to the patient may far outweigh the potential risks. Therefore, each treatment should be determined on a case-by-case basis with regulatory input, ensuring that the risk of the therapy is appropriate for the given condition and patient.

## **Acknowledgements**

The review article was supported by the SafeSciMet programme, a European Community project under the Innovative Medicines Initiative (IMI) Programme through Grant Agreement number 115012. Additional support was provided by the Medical Research Council Centre for Drug Safety Science (grant number G0700654) and the UK Regenerative Medicine Platform Safety Hub (grant number MR/K026739/1).

## References

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. *Science*. 1998;282:1145-1147.
2. Takahashi K, Yamanaka S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. *Cell*. 2006;126:663-676.
3. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. *Cell*. 2007;131:861-872.
4. Sarugaser R, Hanoun L, Keating A, et al. Human Mesenchymal Stem Cells Self-Renew and Differentiate According to a Deterministic Hierarchy. *PLoS ONE*. 2009;4:e6498.
5. Huber TL. Dissecting hematopoietic differentiation using the embryonic stem cell differentiation model. *Int J Dev Biol*. 2010;54:991-1002.
6. Copelan EA. Hematopoietic Stem-Cell Transplantation. *New England Journal of Medicine*. 2006;354:1813-1826.
7. Chao NJ, Emerson SG, Weinberg KI. Stem Cell Transplantation (Cord Blood Transplants). *ASH Education Program Book*. 2004;2004:354-371.
8. Gallico GG, O'Connor NE, Compton CC, et al. Permanent Coverage of Large Burn Wounds with Autologous Cultured Human Epithelium. *New England Journal of Medicine*. 1984;311:448-451.
9. Zheng G-P, Ge M-H, Shu Q, et al. Mesenchymal stem cells in the treatment of pediatric diseases. *World J Pediatr*. 2013;9:197-211.
10. Cyranoski D. Next-generation stem cells cleared for human trial. *Nature*. 2014.
11. Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. *Lancet*. 2012;379:713-720.
12. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. *Nature reviews. Immunology*. 2003;3:879-889.
13. Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient. *PLoS Med*. 2009;6:e1000029.
14. Dlouhy BJ, Awe O, Rao RC, et al. Autograft-derived spinal cord mass following olfactory mucosal cell transplantation in a spinal cord injury patient. *Journal of neurosurgery. Spine*. 2014;21:618-622.
15. Tabakow P, Raisman G, Fortuna W, et al. Functional regeneration of supraspinal connections in a patient with transected spinal cord following transplantation of bulbar olfactory ensheathing cells with peripheral nerve bridging. *Cell Transplant*. 2014.

16. Andrews PW, Matin MM, Bahrami AR, et al. Embryonic stem (ES) cells and embryonal carcinoma (EC) cells: opposite sides of the same coin. *Biochemical Society transactions*. 2005;33:1526-1530.
17. Payne CM, Samuel K, Pryde A, et al. Persistence of functional hepatocyte-like cells in immune-compromised mice. *Liver International*. 2011;31:254-262.
18. Fujikawa T, Oh S-H, Pi L, et al. Teratoma Formation Leads to Failure of Treatment for Type I Diabetes Using Embryonic Stem Cell-Derived Insulin-Producing Cells. *The American Journal of Pathology*. 2005;166:1781-1791.
19. Ben-David U, Gan QF, Golan-Lev T, et al. Selective Elimination of Human Pluripotent Stem Cells by an Oleate Synthesis Inhibitor Discovered in a High-Throughput Screen. *Cell Stem Cell*. 2013;12:167-179.
20. Nguyen PK, Nag D, Wu JC. Methods to assess stem cell lineage, fate and function. *Advanced drug delivery reviews*. 2010;62:1175-1186.
21. Lee AS, Tang C, Cao F, et al. Effects of cell number on teratoma formation by human embryonic stem cells. *Cell Cycle*. 2009;8:2608-2612.
22. Hong So G, Winkler T, Wu C, et al. Path to the Clinic: Assessment of iPSC-Based Cell Therapies In Vivo in a Nonhuman Primate Model. *Cell Reports*. 2014.
23. Alper J. Geron gets green light for human trial of ES cell-derived product. *Nat Biotech*. 2009;27:213-214.
24. Frantz S. Embryonic stem cell pioneer Geron exits field, cuts losses. *Nat Biotech*. 2012;30:12-13.
25. Sverdlov ED, Mineev K. Mutation rate in stem cells: an underestimated barrier on the way to therapy. *Trends in Molecular Medicine*. 2013;19:273-280.
26. Amps K, Andrews PW, Anyfantis G, et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. *Nature Biotechnology*. 2011;29:1132-1144.
27. Ben-David U, Benvenisty N. High Prevalence of Evolutionarily Conserved and Species-Specific Genomic Aberrations in Mouse Pluripotent Stem Cells. *Stem Cells*. 2012;30:612-622.
28. Fazeli A, Liew CG, Matin MM, et al. Altered patterns of differentiation in karyotypically abnormal human embryonic stem cells. *International Journal of Developmental Biology*. 2011;55:175-180.
29. Hovatta O, Jaconi M, Tökönen V, et al. A Teratocarcinoma-Like Human Embryonic Stem Cell (hESC) Line and Four hESC Lines Reveal Potentially Oncogenic Genomic Changes. *PLoS ONE*. 2010;5:e10263.

30. Lund RJ, Nikula T, Rahkonen N, et al. High-throughput karyotyping of human pluripotent stem cells. *Stem Cell Research*. 2012;9:192-195.
31. Mayshar Y, Ben-David U, Lavon N, et al. Identification and Classification of Chromosomal Aberrations in Human Induced Pluripotent Stem Cells. *Cell stem cell*. 2010;7:521-531.
32. Närvä E, Autio R, Rahkonen N, et al. High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. *Nature Biotechnology*. 2010;28:371-377.
33. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. *Nature Reviews Cancer*. 2011;11:268-277.
34. Ben-David U, Mayshar Y, Benvenisty N. Large-Scale Analysis Reveals Acquisition of Lineage-Specific Chromosomal Aberrations in Human Adult Stem Cells. *Cell stem cell*. 2011;9:97-102.
35. Hyka-Nouspikel N, Desmarais J, Gokhale PJ, et al. Deficient DNA Damage Response and Cell Cycle Checkpoints Lead to Accumulation of Point Mutations in Human Embryonic Stem Cells. *Stem Cells*. 2012;30:1901-1910.
36. Draper JS, Smith K, Gokhale P, et al. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. *Nat Biotechnol*. 2004;22:53-54.
37. Lee AS, Tang C, Rao MS, et al. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. *Nature medicine*. 2013;19:998-1004.
38. Sensebé L, Tarte K, Galipeau J, et al. Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. *Cell Stem Cell*. 2012;10:9-10.
39. Ben-David U, Mayshar Y, Benvenisty N. Significant Acquisition of Chromosomal Aberrations in Human Adult Mesenchymal Stem Cells: Response to Sensebé et al. *Cell Stem Cell*. 2012;10:10-11.
40. González F, Boué S, Belmonte JCI. Methods for making induced pluripotent stem cells: Reprogramming à la carte. *Nature Reviews Genetics*. 2011;12:231-242.
41. Warren L, Manos PD, Ahfeldt T, et al. Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA. *Cell stem cell*. 2010;7:618-630.
42. Kim D, Kim C-H, Moon J-I, et al. Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins. *Cell stem cell*. 2009;4:472-476.
43. Fusaki N, Ban H, Nishiyama A, et al. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. *Proc Jpn Acad Ser B Phys Biol Sci*. 2009;85:348-362.



44. Buganim Y, Markoulaki S, van Wietmarschen N, et al. The Developmental Potential of iPSCs Is Greatly Influenced by Reprogramming Factor Selection. *Cell Stem Cell*. 2014;15:295-309.
45. Wu T, Liu Y, Wen D, et al. Histone Variant H2A.X Deposition Pattern Serves as a Functional Epigenetic Mark for Distinguishing the Developmental Potentials of iPSCs. *Cell Stem Cell*. 2014;15:281-294.
46. Miyoshi N, Ishii H, Nagano H, et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. *Cell Stem Cell*. 2011;8:633-638.
47. Hou P, Li Y, Zhang X, et al. Pluripotent Stem Cells Induced from Mouse Somatic Cells by Small-Molecule Compounds. *Science*. 2013;341:651-654.
48. González F, Georgieva D, Vanoli F, et al. Homologous Recombination DNA Repair Genes Play a Critical Role in Reprogramming to a Pluripotent State. *Cell Reports*. 2013;3:651-660.
49. Su R-J, Yang Y, Neises A, et al. Few Single Nucleotide Variations in Exomes of Human Cord Blood Induced Pluripotent Stem Cells. *PLoS ONE*. 2013;8:e59908.
50. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. *Scandinavian journal of immunology*. 2003;57:11-20.
51. Le Blanc K, Tammik C, Rosendahl K, et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. *Experimental hematology*. 2003;31:890-896.
52. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood*. 2005;105:1815-1822.
53. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. *Experimental hematology*. 2002;30:42-48.
54. Majumdar MK, Keane-Moore M, Buyaner D, et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. *Journal of biomedical science*. 2003;10:228-241.
55. Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. *Transplantation*. 2003;75:389-397.
56. Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. *Cell*. 2009;138:271-285.
57. Zheng J, Umikawa M, Zhang S, et al. Ex vivo expanded hematopoietic stem cells overcome the MHC barrier in allogeneic transplantation. *Cell Stem Cell*. 2011;9:119-130.

58. Locatelli F, Lucarelli B, Merli P. Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. *Expert opinion on pharmacotherapy*. 2014;15:23-36.
59. Pasquini MC, Wang Z, Horowitz MM, et al. 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. *Clinical transplants*. 2010:87-105.
60. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. *Nature Reviews Immunology*. 2012;12:443-458.
61. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. *Lancet*. 2004;363:1439-1441.
62. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. *Lancet*. 2008;371:1579-1586.
63. Kim EJ, Kim N, Cho SG. The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation. *Experimental & molecular medicine*. 2013;45:e2.
64. Draper JS, Pigott C, Thomson JA, et al. Surface antigens of human embryonic stem cells: changes upon differentiation in culture. *Journal of anatomy*. 2002;200:249-258.
65. Tachibana M, Amato P, Sparman M, et al. Human Embryonic Stem Cells Derived by Somatic Cell Nuclear Transfer. *Cell*. 2013;153:1228-1238.
66. Chung Young G, Eum Jin H, Lee Jeoung E, et al. Human Somatic Cell Nuclear Transfer Using Adult Cells. *Cell Stem Cell*. 2014;14:777-780.
67. Zhao T, Zhang ZN, Rong Z, et al. Immunogenicity of induced pluripotent stem cells. *Nature*. 2011;474:212-215.
68. Guha P, Morgan JW, Mostoslavsky G, et al. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. *Cell Stem Cell*. 2013;12:407-412.
69. Araki R, Uda M, Hoki Y, et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. *Nature*. 2013;494:100-104.
70. de Almeida PE, Meyer EH, Kooreman NG, et al. Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. *Nat Commun*. 2014;5.
71. Morizane A, Doi D, Kikuchi T, et al. Direct Comparison of Autologous and Allogeneic Transplantation of iPSC-Derived Neural Cells in the Brain of a Nonhuman Primate. *Stem Cell Reports*. 2013;1:283-292.
72. Taylor CJ, Bolton EM, Pocock S, et al. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. *Lancet*. 2005;366:2019-2025.

73. Taylor Craig J, Peacock S, Chaudhry Afzal N, et al. Generating an iPSC Bank for HLA-Matched Tissue Transplantation Based on Known Donor and Recipient HLA Types. *Cell stem cell*. 2012;11:147-152.
74. Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. *Nature Biotechnology*. 2008;26:739-740.
75. Zhang W, Zhao S, Rao W, et al. A novel core-shell microcapsule for encapsulation and 3D culture of embryonic stem cells. *Journal of Materials Chemistry B*. 2013;1:1002-1009.
76. Salick M, Boyer R, Koonce C, et al. Differentiation of Human Embryonic Stem Cells Encapsulated in Hydrogel Matrix Materials. In: Proulx T, ed. *Experimental and Applied Mechanics*, Volume 6: Springer New York; 2011:415-421.
77. Tuch BE, Hughes TC, Evans MDM. Encapsulated pancreatic progenitors derived from human embryonic stem cells as a therapy for insulin-dependent diabetes. *Diabetes/Metabolism Research and Reviews*. 2011;27:928-932.
78. Schulz TC, Young HY, Agulnick AD, et al. A Scalable System for Production of Functional Pancreatic Progenitors from Human Embryonic Stem Cells. *PLoS ONE*. 2012;7:e37004.
79. Lee SH, Hao E, Savinov AY, et al. Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: implications for diabetes cell therapies. *Transplantation*. 2009;87:983-991.
80. Kirk K, Hao E, Lahmy R, et al. Human embryonic stem cell derived islet progenitors mature inside an encapsulation device without evidence of increased biomass or cell escape. *Stem Cell Research*. 2014;12:807-814.
81. Freimark D, Pino-Grace P, Pohl S, et al. Use of Encapsulated Stem Cells to Overcome the Bottleneck of Cell Availability for Cell Therapy Approaches. *Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie*. 2010;37:66-73.
82. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. *Proceedings of the National Academy of Sciences of the United States of America*. 2002;99:8932-8937.
83. Martin MJ, Muotri A, Gage F, et al. Human embryonic stem cells express an immunogenic nonhuman sialic acid. *Nature medicine*. 2005;11:228-232.
84. Jung JW, Kwon M, Choi JC, et al. Familial Occurrence of Pulmonary Embolism after Intravenous, Adipose Tissue-Derived Stem Cell Therapy. *Yonsei Med J*. 2013;54:1293-1296.

85. Syková E, Jendelová P, Urdžíková L, et al. Bone marrow stem cells and polymer hydrogels - Two strategies for spinal cord injury repair. *Cellular and Molecular Neurobiology*. 2006;26:1113-1129.
86. Walczak P, Zhang J, Gilad AA, et al. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. *Stroke*. 2008;39:1569-1574.
87. Bacou F, Boubaker El Andaloussi R, Daussin PA, et al. Transplantation of Adipose Tissue-Derived Stromal Cells Increases Mass and Functional Capacity of Damaged Skeletal Muscle. *Cell Transplant*. 2004;13:103-111.
88. Moscoso I, Barallobre J, de Ilarduya OM, et al. Analysis of different routes of administration of heterologous 5-azacytidine-treated mesenchymal stem cells in a porcine model of myocardial infarction. *Transplantation proceedings*. 2009;41:2273-2275.
89. Li L, Jiang Q, Ding GL, et al. Effects of administration route on migration and distribution of neural progenitor cells transplanted into rats with focal cerebral ischemia, an MRI study. *J Cerebr Blood F Met*. 2010;30:653-662.
90. Zvibel I, Smets F, Soriano H. Anoikis: roadblock to cell transplantation? *Cell Transplant*. 2002;11:621-630.
91. Steward O, Sharp Kelli G, Matsudaira Yee K. Long-Distance Migration and Colonization of Transplanted Neural Stem Cells. *Cell*. 2014;156:385-387.
92. Goldring CE, Duffy PA, Benvenisty N, et al. Assessing the safety of stem cell therapeutics. *Cell Stem Cell*. 2011;8:618-628.
93. Hyun I, Lindvall O, Åhrlund-Richter L, et al. New ISSCR Guidelines Underscore Major Principles for Responsible Translational Stem Cell Research. *Cell stem cell*. 2008;3:607-609.
94. Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. *The New England journal of medicine*. 2006;355:1730-1735.
95. Dobkin BH, Curt A, Guest J. Cellular Transplants in China: Observational Study from the Largest Human Experiment in Chronic Spinal Cord Injury. *Neurorehabilitation and Neural Repair*. 2006;20:5-13.
96. Zarzeczny A, Caulfield T, Ogbogu U, et al. Professional Regulation: A Potentially Valuable Tool in Responding to "Stem Cell Tourism". *Stem Cell Reports*. 3:379-384.
97. Cyranoski D. Stem cells in Texas: Cowboy culture. *Nature*. 2013;494:166-168.
98. Cyranoski D. FDA's claims over stem cells upheld. *Nature*. 2012;487:14.
99. Nature News. Biomedical briefing. *Nature medicine*. 2014;20:226-227.

100. Kuroda T, Yasuda S, Kusakawa S, et al. Highly Sensitive In Vitro Methods for Detection of Residual Undifferentiated Cells in Retinal Pigment Epithelial Cells Derived from Human iPS Cells. *PLoS ONE*. 2012;7:e37342.
101. Lawrenz B, Schiller H, Willbold E, et al. Highly sensitive biosafety model for stem-cell-derived grafts. *Cytotherapy*. 2004;6:212-222.
102. MacIsaac ZM, Shang H, Agrawal H, et al. Long-term in-vivo tumorigenic assessment of human culture-expanded adipose stromal/stem cells. *Experimental cell research*. 2012;318:416-423.
103. Kanemura H, Go MJ, Shikamura M, et al. Tumorigenicity Studies of Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) for the Treatment of Age-Related Macular Degeneration. *PLoS ONE*. 2014;9:e85336.
104. Zhang YS, Wang Y, Wang L, et al. Labeling human mesenchymal stem cells with gold nanocages for in vitro and in vivo tracking by two-photon microscopy and photoacoustic microscopy. *Theranostics*. 2013;3:532-543.
105. Cunningham JJ, Ulbright TM, Pera MF, et al. Lessons from human teratomas to guide development of safe stem cell therapies. *Nature Biotechnology*. 2012;30:849-857.
106. Abe Y, Oshika Y, Ohnishi Y, et al. A xenograft line of human teratocarcinoma established by serial transplantation in severe combined immunodeficient (SCID) mice. *APMIS : acta pathologica, microbiologica, et immunologica Scandinavica*. 1997;105:283-289.
107. Sharpe ME, Morton D, Rossi A. Nonclinical safety strategies for stem cell therapies. *Toxicol Appl Pharmacol*. 2012;262:223-231.
108. Reisner Y, Dagan S. The Trimer mouse: generating human monoclonal antibodies and an animal model for human diseases. *Trends in biotechnology*. 1998;16:242-246.
109. Macchiarelli F, Manz MG, Palucka AK, et al. Humanized mice: are we there yet? *The Journal of experimental medicine*. 2005;202:1307-1311.
110. Rodriguez-Porcel M, Wu JC, Gambhir SS. *Molecular imaging of stem cells*. StemBook. Cambridge (MA); 2008.
111. Kuchmiy AA, Efimov GA, Nedospasov SA. Methods for in vivo molecular imaging. *Biochemistry. Biokhimiia*. 2012;77:1339-1353.
112. Kraitichman DL, Bulte JW. In vivo imaging of stem cells and Beta cells using direct cell labeling and reporter gene methods. *Arteriosclerosis, thrombosis, and vascular biology*. 2009;29:1025-1030.
113. Kraitichman DL, Tatsumi M, Gilson WD, et al. Dynamic Imaging of Allogeneic Mesenchymal Stem Cells Trafficking to Myocardial Infarction. *Circulation*. 2005;112:1451-1461.

114. Brenner W, Aicher A, Eckey T, et al. <sup>111</sup>In-Labeled CD34+ Hematopoietic Progenitor Cells in a Rat Myocardial Infarction Model. *Journal of Nuclear Medicine*. 2004;45:512-518.
115. Kang WJ, Kang HJ, Kim HS, et al. Tissue distribution of <sup>18</sup>F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. 2006;47:1295-1301.
116. McColgan P, Sharma P, Bentley P. Stem Cell Tracking in Human Trials: A Meta-Regression. *Stem Cell Rev Rep*. 2011;7:1031-1040.
117. Zhu J, Zhou L, XingWu F. Tracking neural stem cells in patients with brain trauma. *The New England journal of medicine*. 2006;355:2376-2378.
118. Zhang WY, Ebert AD, Narula J, et al. Imaging cardiac stem cell therapy: translations to human clinical studies. *Journal of cardiovascular translational research*. 2011;4:514-522.
119. de Vries IJM, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. *Nat Biotech*. 2005;23:1407-1413.
120. Ahrens ET, Zhong J. In vivo MRI cell tracking using perfluorocarbon probes and fluorine-19 detection. *NMR in biomedicine*. 2013;26:860-871.
121. Partlow KC, Chen J, Brant JA, et al. <sup>19</sup>F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2007;21:1647-1654.
122. Boehm-Sturm P, Mengler L, Wecker S, et al. In vivo tracking of human neural stem cells with <sup>19</sup>F magnetic resonance imaging. *PLoS One*. 2011;6:e29040.
123. Bible E, Dell'Acqua F, Solanky B, et al. Non-invasive imaging of transplanted human neural stem cells and ECM scaffold remodeling in the stroke-damaged rat brain by (<sup>19</sup>F)- and diffusion-MRI. *Biomaterials*. 2012;33:2858-2871.
124. Ruiz-Cabello J, Barnett BP, Bottomley PA, et al. Fluorine (<sup>19</sup>F) MRS and MRI in biomedicine. *NMR in biomedicine*. 2011;24:114-129.
125. Ahrens ET, Helfer BM, O'Hanlon CF, et al. Clinical cell therapy imaging using a perfluorocarbon tracer and fluorine-19 MRI. *Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine*. 2014;72:1696-1701.
126. Gu E, Chen WY, Gu J, et al. Molecular imaging of stem cells: tracking survival, biodistribution, tumorigenicity, and immunogenicity. *Theranostics*. 2012;2:335-345.

127. Gilad AA, McMahon MT, Walczak P, et al. Artificial reporter gene providing MRI contrast based on proton exchange. *Nat Biotech.* 2007;25:217-219.
128. Wu JC, Spin JM, Cao F, et al. Transcriptional profiling of reporter genes used for molecular imaging of embryonic stem cell transplantation. *Physiological genomics.* 2006;25:29-38.
129. Gyongyosi M, Blanco J, Marian T, et al. Serial noninvasive in vivo positron emission tomographic tracking of percutaneously intramyocardially injected autologous porcine mesenchymal stem cells modified for transgene reporter gene expression. *Circulation. Cardiovascular imaging.* 2008;1:94-103.
130. Pei Z, Lan X, Cheng Z, et al. Multimodality Molecular Imaging to Monitor Transplanted Stem Cells for the Treatment of Ischemic Heart Disease. *PLoS ONE.* 2014;9:e90543.
131. Ray P, De A. Reporter Gene Imaging in Therapy and Diagnosis. *Theranostics.* 2012;2:333-334.
132. Yaghoubi SS, Campbell DO, Radu CG, et al. Positron Emission Tomography Reporter Genes and Reporter Probes: Gene and Cell Therapy Applications. *Theranostics.* 2012;2:374-391.
133. Yaghoubi SS, Couto MA, Chen CC, et al. Preclinical safety evaluation of 18F-FHBG: a PET reporter probe for imaging herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk's expression. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine.* 2006;47:706-715.
134. Yaghoubi SS, Gambhir SS. PET imaging of herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk reporter gene expression in mice and humans using [18F]FHBG. *Nat Protoc.* 2006;1:3069-3075.
135. Wang L, Hu S. Photoacoustic tomography: in vivo imaging from organelles to organs. *Science (New York, N.Y.).* 2012;335:1458-1462.
136. Yao J, Wang LV. Photoacoustic tomography: fundamentals, advances and prospects. *Contrast media & molecular imaging.* 2011;6:332-345.
137. Dokos C, Masjosthusmann K, Rellensmann G, et al. Fatal human metapneumovirus infection following allogeneic hematopoietic stem cell transplantation. *Transplant Infectious Disease.* 2013;15:E97-E101.
138. López MM, Valenzuela JE, Álvarez FC, et al. Long-term problems related to immunosuppression. *Transplant Immunology.* 2006;17:31-35.
139. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. *MMWR. Recommendations And Reports: Morbidity And Mortality Weekly Report. Recommendations And Reports / Centers For Disease Control.* Vol 49. United States: U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control, Epidemiology Program Office; 2000:1.

140. Hurley CK, Raffoux C. World Marrow Donor Association: International standards for unrelated hematopoietic stem cell donor registries. *Bone marrow transplantation*. 2004;34:103-110.
141. Kallianpur AR. Genomic screening and complications of hematopoietic stem cell transplantation: Has the time come? *Bone marrow transplantation*. 2005;35:1-16.
142. Berro M, Mayor NP, Maldonado-Torres H, et al. Association of functional polymorphisms of the transforming growth factor B1 gene with survival and graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation. *Haematologica*. 2010;95:276-283.
143. Viel DO, Tsuneto LT, Sossai CR, et al. IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. *Scandinavian journal of immunology*. 2007;66:703-710.
144. Tate CC, Shear DA, Tate MC, et al. Laminin and fibronectin scaffolds enhance neural stem cell transplantation into the injured brain. *Journal of tissue engineering and regenerative medicine*. 2009;3:208-217.
145. Guan J, Zhu Z, Zhao RC, et al. Transplantation of human mesenchymal stem cells loaded on collagen scaffolds for the treatment of traumatic brain injury in rats. *Biomaterials*. 2013;34:5937-5946.
146. Guyette JP, Gilpin SE, Charest JM, et al. Perfusion decellularization of whole organs. *Nat Protoc*. 2014;9:1451-1468.
147. Zhou Q, Li L, Li J. Stem cells with decellularized liver scaffolds in liver regeneration and their potential clinical applications. *Liver international : official journal of the International Association for the Study of the Liver*. 2014.
148. Sabetkish S, Kajbafzadeh AM, Sabetkish N, et al. Whole-organ tissue engineering: Decellularization and recellularization of three-dimensional matrix liver scaffolds. *Journal of biomedical materials research. Part A*. 2014.
149. Bonandrini B, Figliuzzi M, Papadimou E, et al. Recellularization of well-preserved acellular kidney scaffold using embryonic stem cells. *Tissue engineering. Part A*. 2014;20:1486-1498.
150. Badylak SF, Freytes DO, Gilbert TW. Extracellular matrix as a biological scaffold material: Structure and function. *Acta biomaterialia*. 2009;5:1-13.
151. Fishman JM, Lowdell MW, Urbani L, et al. Immunomodulatory effect of a decellularized skeletal muscle scaffold in a discordant xenotransplantation model. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110:14360-14365.
152. Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ decellularization processes. *Biomaterials*. 2011;32:3233-3243.



153. Song JJ, Ott HC. Organ engineering based on decellularized matrix scaffolds. *Trends Mol Med*. 2011;17:424-432.
154. Daly KA, Liu S, Agrawal V, et al. Damage associated molecular patterns within xenogeneic biologic scaffolds and their effects on host remodeling. *Biomaterials*. 2012;33:91-101.
155. Valentin JE, Badylak JS, McCabe GP, et al. Extracellular matrix bioscaffolds for orthopaedic applications. A comparative histologic study. *The Journal of bone and joint surgery. American volume*. 2006;88:2673-2686.
156. Gunatillake PA, Adhikari R. Biodegradable synthetic polymers for tissue engineering. *Eur Cell Mater*. 2003;5:1-16.
157. Willerth SM, Sakiyama-Elbert SE. Combining stem cells and biomaterial scaffolds for constructing tissues and cell delivery. *StemBook*. Cambridge (MA); 2008.
158. Demirbag B, Huri PY, Kose GT, et al. Advanced cell therapies with and without scaffolds. *Biotechnology journal*. 2011;6:1437-1453.
159. James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. *Physiol Rev*. 2012;92:897-965.
160. Spahn JH, Li W, Kreisel D. Innate immune cells in transplantation. *Current opinion in organ transplantation*. 2014;19:14-19.

### **Table figures**

**Table 1:** *Pluripotent stem cells clinical trials (phase I-III) listed in the International Clinical Trial Registry Platform (ICTRP) by the World Health Organization.*

**Table 2:** *Available assays to assess the tumorigenic risk of stem cell therapeutics, describing the main uses of each technique along with advantages and disadvantage.*

**Table 3:** *Comparison of technologies for stem cell graft tracking in vivo. Further reviewed by James and Gambhir<sup>159</sup>. QD quantum dots; G/RFP, green or red fluorescent protein.*


### **Supplementary figure legends**

**Figure S1: Therapeutic risks of stem cells.** Risk of stem cell therapeutics can be divided into 3 main categories: biodistribution: cell migration, distribution, engraftment and long-term survival; immunogenicity: graft-vs-host disease and other inflammatory/fibrotic conditions; tumorigenicity: genomic aberrations or insertions, cell purity (i.e. transplanted population containing iPSCs/ESCs with inherent teratoma potential) and cell of origin (i.e. the reduced risk of tumorigenicity with ASCs


compared to iPSCs/ESCs, ESCs compared to iPSCs, and neonatal compared with adult cell-derived iPSCs).

**Figure S2: Schematic demonstrating the described potential mechanisms of immune recognition and rejection of stem cell grafts.** (1) *HLA-I incompatibility*. CD8+ cytotoxic T-cells recognize non-self HLA (and co-stimulatory molecules) and initiate an immune response that can lead to rejection. (2) *HLA-II incompatibility*. HLA-II-expressing antigen-presenting cells, present to CD4+ T helper cells resulting in cytokine-induced inflammation and/or activation of B or T cell responses. (3) *Minor histocompatibility complex (mHC) incompatibility*. A selection of proteins expressed in the cell, including mitochondria derived proteins, may bind to and be presented by HLA-I. These can be recognized as mHC antigens, and lead to immune-rejection. (4) *ABO blood group antigen incompatibility*. ABO blood group antigens can be detected by antibodies and activate the complement system. (5) *Natural killer (NK) cells* can also contribute to immune rejection<sup>160</sup>.


**Figure S3: Stem cell imaging/tracking.** Direct labelling of cells requires exposure to labels such as quantum dots, which enter the cytoplasm and can be detected via MRI, PET, SPECT or fluorescent imaging depending on the technique. Indirect labelling requires genetic modification of the cell to insert a reporter gene, which is then detected by the appropriate imaging technique. Details of each technique are listed in table 3. SPIONs: Superparamagnetic iron oxide nanoparticles.



**Figure S1: Therapeutic risks of stem cells.** Risk of stem cell therapeutics can be divided into 3 main categories: biodistribution: cell migration, distribution, engraftment and long-term survival; immunogenicity: graft-vs-host disease and other inflammatory/fibrotic conditions; tumorigenicity: genomic aberrations or insertions, cell purity (i.e. transplanted population containing iPSCs/ESCs with inherent teratoma potential) and cell of origin (i.e. the reduced risk of tumorigenicity with ASCs compared to iPSCs/ESCs, ESCs compared to iPSCs, and neonatal compared with adult cell-derived iPSCs).



**Figure S2: Schematic demonstrating the described potential mechanisms of immune recognition and rejection of stem cell grafts.** (1) *HLA-I incompatibility*. CD8+ cytotoxic T-cells recognize non-self HLA (and co-stimulatory molecules) and initiate an immune response that can lead to rejection. (2) *HLA-II incompatibility*. HLA-II-expressing antigen-presenting cells, present to CD4+ T helper cells resulting in cytokine-induced inflammation and/or activation of B or T cell responses. (3) *Minor histocompatibility complex (mHC) incompatibility*. A selection of proteins expressed in the cell, including mitochondria derived proteins, may bind to and be presented by HLA-I. These can be recognized as mHC antigens, and lead to immune-rejection. (4) *ABO blood group antigen incompatibility*. ABO blood group antigens can be detected by antibodies and activate the complement system. (5) *Natural killer (NK) cells* can also contribute to immune rejection.



**Figure S3: Stem cell imaging/tracking.** Direct labelling of cells requires exposure to labels such as quantum dots, which enter the cytoplasm and can be detected via MRI, PET, SPECT or fluorescent imaging depending on the technique. Indirect labelling requires genetic modification of the cell to insert a reporter gene, which is then detected by the appropriate imaging technique. Details of each technique are listed in table 3. SPIONs: Superparamagnetic iron oxide nanoparticles.